...and adjunct professor of medicine at Yale University . Thomas Collet, president and CEO of Meditrina Pharmaceuticals Inc....
...be advantageous" over current estrogen-suppressing therapies, said James Symons, VP of clinical development at Meditrina. Meditrina's...
...Lausanne, Switzerland Galenica Ltd. (SIX:GALN), Bern, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Meditrina Pharmaceuticals Inc....

...mice. AstraZeneca plc, Novartis AG and Pfizer Inc. market aromatase inhibitors to treat breast cancer. Meditrina Pharmaceuticals Inc.'s...

...cancer include AstraZeneca plc's Arimidex anastrozole, Novartis AG's Femara letrozole and Pfizer Inc.'s Aromasin exemestane. Meditrina Pharmaceuticals Inc....

...Next quarter, Meditrina will begin a double-blind, placebo-controlled, U.S. Phase IIa trial of MDI-676 in combination...
...U.S. Phase IIa trial of MDI-676 in combination with fixed-dose estrogen and progestin oral contraceptives. Meditrina Pharmaceuticals Inc....

...AstraZeneca granted Meditrina exclusive, worldwide rights to IP covering aromatase inhibitors in combination with estrogen and...
...inhibitors in combination with estrogen and progestin to treat endometriosis. Financial terms were not disclosed. Meditrina's...
...trial for endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina Pharmaceuticals Inc....

...which is to inhibit the aromatase enzyme that converts certain androgens to estrogen - Meditrina Pharmaceuticals Inc....
...to prevent regrowth and recurrent bleeding. Because aromatase inhibitors decrease the amount of circulating estrogen, Meditrina...
...on June 3, 2011. Femathina ( MPI-674 ) is an undisclosed marketed aromatase inhibitor that Meditrina...

...began the placebo-controlled, U.S. Phase II M001 trial of oral MPI-674 in 68 healthy females. Meditrina Pharmaceuticals Inc....